PTEN and breast carcinoma: In summary, ATO inhibits the expression level of p-AKT by positively regulating the expression level of RhoB and increases the expression level of PTEN, thereby inhibiting the PI3K/AKT pathway and exerting its inhibitory effect on breast cancer.